CADTH is working with a group of international health technology assessment (HTA) organizations to share learnings about the development of economic models that consider disease pathways.

Globally, HTA organizations are seeing a growing number of drugs available for the same disease area. This can create complex treatment pathways for patients and introduce challenges for public payers. Using different cost-effectiveness models every time a new treatment is evaluated can lead to unnecessary repetition in processes and inconsistencies in modelling approaches and evidence.

Current consultation status: Closed 
Consultation period: January 25 to February 22, 2024

CADTH is taking steps to help drug sponsors enhance the budget impact analyses (BIAs) included in the submissions they file with our Drug Reimbursement Review program.